ANAPTYSBIO INC
ANABNASDAQ🏆 #2149 by market capEarnings Nov 10 · PostUS Equity
$48.64▼ $1.86 (−3.68%)
Market closed · at closeTrack ANAB
Get earnings, price moves & breaking news on Telegram
24h▼ 3.7%
7d▼ 0.2%
14d▲ 4.4%
30d▼ 3.2%
ytd▲ 0.3%
1y▲ 33.2%
🏦Market Cap
$1.45B
Small Cap
📈Revenue Growth (YoY)
92.9%
High Growth
📊Gross Margin
—
💵FCF Margin
41.2%
Strong
⚖️P/S Ratio
6.2x
Fair
Otter Score
—
Insufficient data
ANAPTYSBIO INC
ANABAnalyst Ratings
Price
$48.64
Total
23
Raised
0
Lowered
3
Avg PT
$79.17
H / L
$95 / $70
| Institution | Action | Rating | Date | Upside | |
|---|---|---|---|---|---|
JP Morgan | Reiterated | Overweight | 2026-09-30 | $32.00 | −34.20% |
HC Wainwright & Co. | Reiterated | Buy | 2026-09-24 | — | — |
Leerink Partners | Reiterated | Outperform | 2026-09-23 | $81.00 | +66.50% |
TD Cowen | Reiterated | Buy | 2026-08-25 | — | — |
Barclays | Reiterated | Overweight | 2026-05-13 | $75.00 | +54.20% |
UBS | Reiterated | Buy | 2026-05-13 | $76.00 | +56.30% |
Piper Sandler | Reiterated | Overweight | 2026-05-04 | $80.00 | +64.50% |
Wedbush | Reiterated | Outperform | 2026-03-12 | $50.00 | +2.80% |
Truist Securities | Reiterated | Hold | 2026-03-09 | — | — |
Stifel | Reiterated | Buy | 2026-03-05 | — | — |
Wells Fargo | Reiterated | Overweight | 2025-11-05 | — | — |
Guggenheim | Reiterated | Buy | 2025-11-05 | $140.00 | +187.80% |
BTIG | Downgraded | Buy → Neutral | 2024-12-02 | — | — |
Raymond James | Downgraded | Outperform → Market Perform | 2023-01-06 | — | — |
Credit Suisse | Reiterated | Neutral | 2020-05-07 | — | — |
SunTrust Robinson Humphrey | Reiterated | Hold | 2020-03-03 | — | — |
H.C. Wainwright | Reiterated | Buy | 2018-12-20 | $95.00 | +95.30% |
Cantor Fitzgerald | Reiterated | Overweight | 2018-08-28 | — | — |
JMP Securities | Reiterated | Market Outperform | 2018-08-15 | — | — |
RBC Capital | Downgraded | Outperform → Sector Perform | 2018-04-04 | — | — |
Stifel Nicolaus | Reiterated | Buy | 2018-03-27 | $85.00 | +74.80% |
Jefferies | Reiterated | Buy | 2017-11-09 | — | — |
Baird | Reiterated | Outperform | 2017-07-11 | — | — |
Institution
JP Morgan
Reiterated · Overweight · 2026-09-30
$32.00
−34.20%
HC Wainwright & Co.
Reiterated · Buy · 2026-09-24
—
—
Leerink Partners
Reiterated · Outperform · 2026-09-23
$81.00
+66.50%
TD Cowen
Reiterated · Buy · 2026-08-25
—
—
Barclays
Reiterated · Overweight · 2026-05-13
$75.00
+54.20%
UBS
Reiterated · Buy · 2026-05-13
$76.00
+56.30%
Piper Sandler
Reiterated · Overweight · 2026-05-04
$80.00
+64.50%
Wedbush
Reiterated · Outperform · 2026-03-12
$50.00
+2.80%
Truist Securities
Reiterated · Hold · 2026-03-09
—
—
Stifel
Reiterated · Buy · 2026-03-05
—
—
Wells Fargo
Reiterated · Overweight · 2025-11-05
—
—
Guggenheim
Reiterated · Buy · 2025-11-05
$140.00
+187.80%
BTIG
Downgraded · Buy → Neutral · 2024-12-02
—
—
Raymond James
Downgraded · Outperform → Market Perform · 2023-01-06
—
—
Credit Suisse
Reiterated · Neutral · 2020-05-07
—
—
SunTrust Robinson Humphrey
Reiterated · Hold · 2020-03-03
—
—
H.C. Wainwright
Reiterated · Buy · 2018-12-20
$95.00
+95.30%
Cantor Fitzgerald
Reiterated · Overweight · 2018-08-28
—
—
JMP Securities
Reiterated · Market Outperform · 2018-08-15
—
—
RBC Capital
Downgraded · Outperform → Sector Perform · 2018-04-04
—
—
Stifel Nicolaus
Reiterated · Buy · 2018-03-27
$85.00
+74.80%
Jefferies
Reiterated · Buy · 2017-11-09
—
—
Baird
Reiterated · Outperform · 2017-07-11
—
—
One row per institution · price target from the firm's latest published target
StockOtter · stockotter.space